Replies to post #382140 on Innovation Pharmaceuticals Inc (IPIX)

[Minnesinger]

I'm not sure that question will be as relevant...

if PFE's drug gets EUA. If so, the intent to treat population of our drug will become significantly diminished. Simply put, far fewer patients will progress from mild to moderate/severe. It's that simple.

There's nothing nefarious with today's IPIX action. Dispassionate investors recognize that PFE's drug will disaffect our potential market -- at least for CV19. Someone else commented that we need to focus on the big picture of a broad-spectrum antiviral. I wholeheartedly agree and it's my hope that the CV19 results put us a step or two closer to that realization. I'll also add that I recognize that Brilacidin has potential for other indications, but it will be much more difficult (and protracted) to realize that potential without partner/license money from antiviral.